TY - JOUR
T1 - Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases
AU - Baumann, Ralf
AU - Untersmayr, Eva
AU - Zissler, Ulrich M.
AU - Eyerich, Stefanie
AU - Adcock, Ian M.
AU - Brockow, Knut
AU - Biedermann, Tilo
AU - Ollert, Markus
AU - Chaker, Adam M.
AU - Pfaar, Oliver
AU - Garn, Holger
AU - Thwaites, Ryan S.
AU - Togias, Alkis
AU - Kowalski, Marek L.
AU - Hansel, Trevor T.
AU - Jakwerth, Constanze A.
AU - Schmidt-Weber, Carsten B.
N1 - Funding Information:
We particularly thank Maryam Poorafshar, Magnus Molin, and Jeronimo Carnes for their advice and experience from the diagnostic and pharmaceutical industry. The authors thank the European Academy of Allergy and Clinical Immunology (EAACI) for financial support of the task force. We also thank EIT Health for their visionary support of innovation projects in this area. EIT Health is a body of the EU and receives funding from the H2020 program.
Funding Information:
We particularly thank Maryam Poorafshar, Magnus Molin, and Jeronimo Carnes for their advice and experience from the diagnostic and pharmaceutical industry. The authors thank the European Academy of Allergy and Clinical Immunology (EAACI) for financial support of the task force. We also thank EIT Health for their visionary support of innovation projects in this area. EIT Health is a body of the EU and receives funding from the H2020 program.
Funding Information:
Prof. Adcock, Prof. Brockow, Prof. Eyerich, Prof. Garn, Prof. Ollert, Prof. Untersmayr, Prof. Togias, Dr Thwaites, and Dr Zissler have nothing to disclose. Prof. Schmidt‐Weber and Dr Jakwerth reports grants from Federal Ministry of Education and Research and European Institute of Innovation & Technology (EIT), during the conduct of the study. Prof. Schmidt‐Weber reports personal fees from Allergopharma and Allergy Therapeutics. Dr. Pfaar reports grants and personal fees from ALK‐Abelló, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Lofarma, grants from Biomay, grants from Circassia, grants and personal fees from ASIT Biotech Tools S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal fees from MEDA Pharma/MYLAN, grants and personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Indoor Biotechnologies, grants and personal fees from Glaxo Smith Kline, personal fees from Astellas Pharma Global, personal fees from EUFOREA, personal fees from ROXALL Medizin, personal fees from Novartis, personal fees from Sanofi‐Aventis and Sanofi‐Genzyme, personal fees from Med Update Europe GmbH, personal fees from streamedup! GmbH, grants from Pohl‐Boska. Prof. Baumann reports grants from Phadia, part of Thermo Fisher Scientific, and grants from European Institute of Innovation & Technology (EIT), during the conduct of the study. Dr Hansel holds shares of Mucosal Diagnostics. Prof. Biedermann reports grants and personal fees from Phadia‐Thermo Fisher during the conduct of the study. Dr Chaker reports grants for clinical studies and research and other from Allergopharma, ALK‐Abello, AstraZeneca, Bencard/ Allergen Therapeutics, ASIT Biotech, Immunotek, Lofarma, GSK, Novartis, LETI, Roche, Sanofi Genzyme, Zeller and from the European Institute of Technology (EIT); and has received travel support from the European Academy of Allergy and Clinical Immunology (EAACI), DGAKI, and SMI, all outside the submitted work. Prof. Kowalski reports grants from EIT.
Publisher Copyright:
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2021/4
Y1 - 2021/4
N2 - Allergic diseases of the (upper and lower) airways, the skin and the gastrointestinal tract, are on the rise, resulting in impaired quality of life, decreased productivity, and increased healthcare costs. As allergic diseases are mostly tissue-specific, local sampling methods for respective biomarkers offer the potential for increased sensitivity and specificity. Additionally, local sampling using noninvasive or minimally invasive methods can be cost-effective and well tolerated, which may even be suitable for primary or home care sampling. Non- or minimally invasive local sampling and diagnostics may enable a more thorough endotyping, may help to avoid under- or overdiagnosis, and may provide the possibility to approach precision prevention, due to early diagnosis of these local diseases even before they get systemically manifested and detectable. At the same time, dried blood samples may help to facilitate minimal-invasive primary or home care sampling for classical systemic diagnostic approaches. This EAACI position paper contains a thorough review of the various technologies in allergy diagnosis available on the market, which analytes or biomarkers are employed, and which samples or matrices can be used. Based on this assessment, EAACI position is to drive these developments to efficiently identify allergy and possibly later also viral epidemics and take advantage of comprehensive knowledge to initiate preventions and treatments.
AB - Allergic diseases of the (upper and lower) airways, the skin and the gastrointestinal tract, are on the rise, resulting in impaired quality of life, decreased productivity, and increased healthcare costs. As allergic diseases are mostly tissue-specific, local sampling methods for respective biomarkers offer the potential for increased sensitivity and specificity. Additionally, local sampling using noninvasive or minimally invasive methods can be cost-effective and well tolerated, which may even be suitable for primary or home care sampling. Non- or minimally invasive local sampling and diagnostics may enable a more thorough endotyping, may help to avoid under- or overdiagnosis, and may provide the possibility to approach precision prevention, due to early diagnosis of these local diseases even before they get systemically manifested and detectable. At the same time, dried blood samples may help to facilitate minimal-invasive primary or home care sampling for classical systemic diagnostic approaches. This EAACI position paper contains a thorough review of the various technologies in allergy diagnosis available on the market, which analytes or biomarkers are employed, and which samples or matrices can be used. Based on this assessment, EAACI position is to drive these developments to efficiently identify allergy and possibly later also viral epidemics and take advantage of comprehensive knowledge to initiate preventions and treatments.
KW - anaphylaxis
KW - asthma
KW - atopic dermatitis
KW - food allergy
KW - noninvasive diagnosis
UR - http://www.scopus.com/inward/record.url?scp=85104209429&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/33128851
U2 - 10.1111/all.14645
DO - 10.1111/all.14645
M3 - Article
C2 - 33128851
AN - SCOPUS:85104209429
SN - 0105-4538
VL - 76
SP - 1010
EP - 1023
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 4
ER -